Experimental drug chidamide targets Hard-to-Treat blood cancer
NCT ID NCT05833724
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase II trial tests the drug chidamide in people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The study aims to see if chidamide can shrink tumors and how safe it is. Participants take chidamide twice a week, and doctors monitor their response using scans and clinical exams.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chidamide (also called Tucidinostat or HBI-8000)
- What this could lead to
- If successful, chidamide could offer a new treatment option for people with this rare and aggressive blood cancer that has not responded to other therapies.
- What could go wrong
- This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The drug may cause side effects and may not shrink tumors in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital, Kaohsiung
RECRUITINGKaohsiung City, Taiwan
Contact
-
Chang Gung Memorial Hospital, Linkou
RECRUITINGTaoyuan, Taiwan
Contact
-
Far eastern memorial hospital
RECRUITINGNew Taipei City, 220, Taiwan
Contact
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact
-
Taichung Veterans General Hospital
RECRUITINGTaichung, Taiwan
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.